Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
Launched by GIL JOON SUH · May 17, 2012
Trial Information
Current as of April 28, 2025
Withdrawn
Keywords
ClinConnect Summary
This study is a single center, randomized, double-blind, placebo controlled trial.
After the diagnosis of severe sepsis and septic shock, enrolled patients will be randomized. Then, selenium or placebo will be intravenously administered to them for 7 days. Hemodynamic and laboratory data will be recorded for 7 days and additional serum samples will be obtained at 0, 24, 72, and 168 hours post-treatment and stored. Mortality will be observed for 28 days.
An interim analysis will be conducted by the independent data safety monitoring board.
Serum selenium levels will be measured from the s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 18 or older
- • clinical diagnosis of severe sepsis or septic shock
- Exclusion Criteria:
- • pregnancy or breast feeding
- • age younger than 18
- • advanced directive state to withhold treatment
- • known allergy to selenium
- • CPR or death within 24 hours after the diagnosis of severe sepsis or septic shock
- • advanced malignancy without further treatment plan
About Gil Joon Suh
Gil Joon Suh is a dedicated clinical trial sponsor with a focus on advancing innovative therapies and improving patient outcomes. With a commitment to rigorous scientific standards and ethical practices, Gil Joon Suh leads the development of cutting-edge clinical research programs that span various therapeutic areas. The organization collaborates with leading research institutions and healthcare professionals to ensure the highest quality of clinical trials, fostering a culture of transparency and accountability. Through its strategic initiatives, Gil Joon Suh aims to contribute significantly to the advancement of medical science and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Gil Joon Suh, professor
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials